Patents by Inventor Aron Katz

Aron Katz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10094827
    Abstract: The present invention relates to a method of designing an inhibitor of the binding of HIV (human immunodeficiency virus) glycoprotein (gp)120 to a CD4-receptor or to the integrin alpha4 beta7 (a4b7). The inhibitor interacts with at least two amino acid residues comprised in six motifs within the 3-dimensional structure of gp120. Also provided are compounds, pharmaceutical compositions thereof and uses thereof in the development of an inhibitor of the binding of a HIV gp120 to a CD4-receptor or an integrin alpha4 beta7 (a4b7). The inhibitors are useful for the prevention or treatment of an HIV infection and/or diseases associated with an HIV infection.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: October 9, 2018
    Assignee: KFLP BIOTECH, LLC
    Inventors: Andrey Vinnik, Peter Fedichev, Maxim Kholin, Christopher Molloy, Aron Katz
  • Patent number: 9610264
    Abstract: The present invention provides compounds and pharmaceutical compositions for use in treating or preventing retroviral infections, in particular HIV infections and/or diseases associated with an HIV infection.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: April 4, 2017
    Assignee: KFLP BIOTECH, LLC
    Inventors: Andrey Vinnik, Peter Fedichev, Maxim Kholin, Christopher Molloy, Aron Katz, Alexander Kadushkin
  • Publication number: 20160313325
    Abstract: The present invention relates to a method of designing an inhibitor of the binding of HIV (human immunodeficiency virus) glycoprotein (gp)120 to a CD4-receptor or to the integrin alpha4 beta7 (a4b7). The inhibitor interacts with at least two amino acid residues comprised in six motifs within the 3-dimensional structure of gp120. Also provided are compounds, pharmaceutical compositions thereof and uses thereof in the development of an inhibitor of the binding of a HIV gp120 to a CD4-receptor or an integrin alpha4 beta7 (a4b7). The inhibitors are useful for the prevention or treatment of an HIV infection and/or diseases associated with an HIV infection.
    Type: Application
    Filed: July 12, 2016
    Publication date: October 27, 2016
    Inventors: Andrey Vinnik, Peter Fedichev, Maxim Kholin, Christopher Molloy, Aron Katz
  • Patent number: 9422527
    Abstract: The present invention relates to a method of designing an inhibitor of the binding of HIV (human immunodeficiency virus) glycoprotein (gp)120 to a CD4-receptor or to the integrin alpha4 beta7 (a4b7). The inhibitor interacts with at least two amino acid residues comprised in six motifs within the 3-dimensional structure of gp120. Also provided are compounds, pharmaceutical compositions thereof and uses thereof in the development of an inhibitor of the binding of a HIV gp120 to a CD4-receptor or an integrin alpha4 beta7 (a4b7). The inhibitors are useful for the prevention or treatment of an HIV infection and/or diseases associated with an HIV infection.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: August 23, 2016
    Assignee: KFLP BIOTECH, LLC
    Inventors: Andrey Vinnik, Peter Fedichev, Maxim Kholin, Christopher Molloy, Aron Katz
  • Publication number: 20150265557
    Abstract: The present invention provides compounds and pharmaceutical compositions for use in treating or preventing retroviral infections, in particular HIV infections and/or diseases associated with an HIV infection.
    Type: Application
    Filed: September 26, 2013
    Publication date: September 24, 2015
    Inventors: Andrey Vinnik, Peter Fedichev, Maxim Kholin, Christopher Molloy, Aron Katz, Alexander Kadushkin
  • Publication number: 20140038168
    Abstract: The present invention relates to a method of designing an inhibitor of the binding of HIV (human immunodeficiency virus) glycoprotein (gp)120 to a CD4-receptor or to the integrin alpha4 beta7 (a4b7). The inhibitor interacts with at least two amino acid residues comprised in six motifs within the 3-dimensional structure of gp120. Also provided are compounds, pharmaceutical compositions thereof and uses thereof in the development of an inhibitor of the binding of a HIV gp120 to a CD4-receptor or an integrin alpha4 beta7 (a4b7). The inhibitors are useful for the prevention or treatment of an HIV infection and/or diseases associated with an HIV infection.
    Type: Application
    Filed: October 27, 2011
    Publication date: February 6, 2014
    Applicant: KFLP BIOTECH, LLC
    Inventors: Andrey Vinnik, Peter Fedichev, Maxim Kholin, Christopher Molloy, Aron Katz
  • Patent number: 8366935
    Abstract: A method is described for producing an extract of Phyllanthus comprising the steps of: (a) extracting Phyllanthus components with a solvent; (b) fractionating the extract obtained in the preceding step on the basis of hydrophobicity; (c) collecting and combining fractions that correspond in hydrophobicity to elute fractions resulting from 10-50% methanol elution steps, wherein the elute fractions are obtained by low pressure vacuum liquid chromatography (VLC) using a C18 reversed-phase lipophilic column and a water/methanol gradient system, wherein the gradient system is based on an initial elution step of loading the column with 100% water, on intermediate elution steps with gradually decreasing water content and on a terminal elution step loading the column with 100% methanol; and (d) optionally drying the extract obtained in step (c).
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: February 5, 2013
    Inventors: Aron Katz, Christopher Molloy, Mark Stuart Butler, Brinda Somanadhan
  • Publication number: 20100190726
    Abstract: A method is described for producing an extract of Phyllanthus comprising the steps of: (a) extracting Phyllanthus components with a solvent; (b) fractionating the extract obtained in the preceding step on the basis of hydrophobicity; (c) collecting and combining fractions that correspond in hydrophobicity to elute fractions resulting from 10-50% methanol elution steps, wherein the elute fractions are obtained by low pressure vacuum liquid chromatography (VLC) using a C18 reversed-phase lipophilic column and a water/methanol gradient system, wherein the gradient system is based on an initial elution step of loading the column with 100% water, on intermediate elution steps with gradually decreasing water content and on a terminal elution step loading the column with 100% methanol; and (d) optionally drying the extract obtained in step (c).
    Type: Application
    Filed: December 21, 2009
    Publication date: July 29, 2010
    Applicant: Phytrix JV, LLC
    Inventors: Aron Katz, Christopher Molloy, Mark Stuart Butler, Brinda Somanadhan